JP2017531659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531659A5 JP2017531659A5 JP2017518466A JP2017518466A JP2017531659A5 JP 2017531659 A5 JP2017531659 A5 JP 2017531659A5 JP 2017518466 A JP2017518466 A JP 2017518466A JP 2017518466 A JP2017518466 A JP 2017518466A JP 2017531659 A5 JP2017531659 A5 JP 2017531659A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- factor
- composition according
- colloidal particles
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000002245 particle Substances 0.000 claims 7
- 150000002632 lipids Chemical class 0.000 claims 5
- 229960000182 blood factors Drugs 0.000 claims 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- 102100015239 F2 Human genes 0.000 claims 1
- 102100009906 F7 Human genes 0.000 claims 1
- 102100006624 F9 Human genes 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010014172 Factor V Proteins 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 229960000301 Factor VIII Drugs 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 229940012414 Factor VIIa Drugs 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 108010074864 Factor XI Proteins 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 108010071289 Factor XIII Proteins 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229960000856 Protein C Drugs 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 108010094028 Prothrombin Proteins 0.000 claims 1
- 229940039716 Prothrombin Drugs 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 201000005114 blood coagulation disease Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960004222 factor IX Drugs 0.000 claims 1
- 229940012413 factor VII Drugs 0.000 claims 1
- 229940012426 factor X Drugs 0.000 claims 1
- 229940012444 factor XIII Drugs 0.000 claims 1
- 108060005018 mobB Proteins 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Claims (15)
- 血液因子と、生体適合性親水性ポリマーで誘導体化された0.5〜20モル%の両親媒性脂質を含有するコロイド粒子と、を含み、
前記血液因子が前記コロイド粒子に封入されていない、皮下投与用医薬組成物。 - 前記コロイド粒子が実質的に中性であり、および前記ポリマーが実質的に正味の電荷を有さない、請求項1に記載の医薬組成物。
- 前記コロイド粒子が、0.03〜0.4ミクロン(μm)の平均粒径を有する、請求項1または2に記載の医薬組成物。
- 前記両親媒性脂質が天然源または合成源由来のリン脂質である、請求項1〜3のいずれかに記載の医薬組成物。
- 前記両親媒性脂質がカルバメート結合非荷電性リポポリマーである、請求項1〜3のいずれかに記載の医薬組成物。
- 前記コロイド粒子が、天然源または合成源のいずれかから得られた第2の両親媒性脂質をさらに含む、請求項1〜5のいずれかに記載の医薬組成物。
- 前記コロイド粒子が、パルミトイル−オレオイルホスファチジルコリン(POPC)および1,2−ジステアロイル−sn−グリセロ−3−ホスホエタノール−アミン(DSPE)を、(POPC:DSPE)=85〜99:15〜1の比で含む、請求項6に記載の医薬組成物。
- コレステロールが前記組成物に補充される、請求項6に記載の医薬組成物。
- 前記生体適合性親水性ポリマーが、ポリアルキルエーテル、ポリ乳酸およびポリグリコール酸からなる群より選択される、請求項1〜8のいずれか1項に記載の医薬組成物。
- 前記ポリエチレングリコールが500〜5000ダルトンの分子量を有する、請求項9に記載の医薬組成物。
- 前記誘導体化された両親媒性脂質が、1,2−ジステアロイル−sn−グリセロ−3−ホスホエタノール−アミン−N−[ポリ−(エチレングリコール)]である、請求項9または10に記載の医薬組成物。
- 前記血液因子タンパク質またはポリペプチドが、第VIII因子、第VIIa因子、第VII因子、第IX因子、第X因子、第Xa因子、第XI因子、第V因子、第XII因子、第XIII因子、フォン・ヴィレブランド因子(vWF)、プロトロンビンもしくはプロテインCおよび/またはそれらのフラグメントからなる群より選択される、請求項1〜11のいずれか1項に記載の医薬組成物。
- 前記組成物が、他の治療的に活性な化合物をさらに含む、請求項1〜12のいずれか1項に記載の医薬組成物。
- 血液凝固疾患または外傷の治療のために使用される、請求項1〜13のいずれか1項に記載の医薬組成物。
- 血液因子に対する抗体ができている患者に皮下投与されることによって使用される、請求項14に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1417589.7A GB201417589D0 (en) | 2014-10-06 | 2014-10-06 | Pharmaceutical Formulations |
GB1417589.7 | 2014-10-06 | ||
PCT/EP2015/073003 WO2016055447A1 (en) | 2014-10-06 | 2015-10-06 | Pharmaceutical formulations of pegylated liposomes and blood coagulation factors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020129101A Division JP2020183446A (ja) | 2014-10-06 | 2020-07-30 | Peg化リポソームおよび血液凝固因子の製剤処方 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017531659A JP2017531659A (ja) | 2017-10-26 |
JP2017531659A5 true JP2017531659A5 (ja) | 2018-11-15 |
Family
ID=51946871
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017518466A Pending JP2017531659A (ja) | 2014-10-06 | 2015-10-06 | Peg化リポソームおよび血液凝固因子の製剤処方 |
JP2020129101A Pending JP2020183446A (ja) | 2014-10-06 | 2020-07-30 | Peg化リポソームおよび血液凝固因子の製剤処方 |
JP2022168146A Pending JP2023002687A (ja) | 2014-10-06 | 2022-10-20 | Peg化リポソームおよび血液凝固因子の製剤処方 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020129101A Pending JP2020183446A (ja) | 2014-10-06 | 2020-07-30 | Peg化リポソームおよび血液凝固因子の製剤処方 |
JP2022168146A Pending JP2023002687A (ja) | 2014-10-06 | 2022-10-20 | Peg化リポソームおよび血液凝固因子の製剤処方 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20170304203A1 (ja) |
EP (1) | EP3204034B9 (ja) |
JP (3) | JP2017531659A (ja) |
AU (1) | AU2015330102B2 (ja) |
BR (1) | BR112017007031A2 (ja) |
CA (1) | CA2994891C (ja) |
ES (1) | ES2954134T3 (ja) |
GB (1) | GB201417589D0 (ja) |
HR (1) | HRP20230985T1 (ja) |
HU (1) | HUE063656T2 (ja) |
MX (1) | MX2017004378A (ja) |
PL (1) | PL3204034T3 (ja) |
RS (1) | RS64461B1 (ja) |
RU (1) | RU2737291C2 (ja) |
WO (1) | WO2016055447A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
JP6825010B2 (ja) * | 2016-05-26 | 2021-02-03 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 遠心法によるリポソーム調製のための方法及び装置 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
ATE179599T1 (de) | 1993-08-06 | 1999-05-15 | Opperbas Holding Bv | Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen |
IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
US6156337A (en) * | 1994-07-08 | 2000-12-05 | Opperbas Holding B.V. | Method for high loading of vesicles with biopolymeric substances |
US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
WO1999055306A1 (en) * | 1998-04-27 | 1999-11-04 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
KR100758158B1 (ko) | 1999-07-14 | 2007-09-12 | 알자 코포레이션 | 중성 지질중합체 및 그를 함유하는 리포솜 조성물 |
EP1280548B1 (en) * | 2000-05-03 | 2013-12-11 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor VII |
US20070141135A1 (en) | 2005-06-29 | 2007-06-21 | Balu-Lyer Sathy V | Compositions and methods for less immunogenic protein-lipid complexes |
US20030232075A1 (en) | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
ES2307009T3 (es) | 2003-04-15 | 2008-11-16 | Opperbas Holding B.V. | Composicion farmaceutica que contiene proteinas y/o polipeptidos y particulas coloidales. |
US20100143326A1 (en) * | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
US20090117087A1 (en) | 2007-04-13 | 2009-05-07 | Wake Forest University | Methods and compositions for printing biologically compatible nanotube composites of autologous tissue |
ES2682075T3 (es) | 2009-06-03 | 2018-09-18 | Sequessome Technology Holdings Limited | Formulaciones para el tratamiento de dolor de tejido profundo |
CN102770162B (zh) | 2009-08-21 | 2016-09-28 | 靶向递送技术有限公司 | 囊泡制剂 |
GB201007356D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
TW201240664A (en) * | 2010-09-01 | 2012-10-16 | Portola Pharm Inc | Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor |
MD20140123A2 (ro) | 2012-04-16 | 2015-04-30 | Cantab Biopharmaceuticals Patents Limited | Agenţi terapeutici optimizaţi pentru administrare subcutanată |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
-
2014
- 2014-10-06 GB GBGB1417589.7A patent/GB201417589D0/en not_active Ceased
-
2015
- 2015-10-06 PL PL15775444.1T patent/PL3204034T3/pl unknown
- 2015-10-06 RS RS20230695A patent/RS64461B1/sr unknown
- 2015-10-06 BR BR112017007031A patent/BR112017007031A2/pt active Search and Examination
- 2015-10-06 RU RU2017115831A patent/RU2737291C2/ru active
- 2015-10-06 MX MX2017004378A patent/MX2017004378A/es unknown
- 2015-10-06 EP EP15775444.1A patent/EP3204034B9/en active Active
- 2015-10-06 ES ES15775444T patent/ES2954134T3/es active Active
- 2015-10-06 HU HUE15775444A patent/HUE063656T2/hu unknown
- 2015-10-06 WO PCT/EP2015/073003 patent/WO2016055447A1/en active Application Filing
- 2015-10-06 AU AU2015330102A patent/AU2015330102B2/en active Active
- 2015-10-06 HR HRP20230985TT patent/HRP20230985T1/hr unknown
- 2015-10-06 JP JP2017518466A patent/JP2017531659A/ja active Pending
- 2015-10-06 CA CA2994891A patent/CA2994891C/en active Active
- 2015-10-06 US US15/517,148 patent/US20170304203A1/en not_active Abandoned
-
2018
- 2018-08-01 US US16/052,300 patent/US11484499B2/en active Active
-
2020
- 2020-07-30 JP JP2020129101A patent/JP2020183446A/ja active Pending
-
2022
- 2022-10-20 JP JP2022168146A patent/JP2023002687A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pan et al. | Recent advances on polymeric hydrogels as wound dressings | |
Montazerian et al. | Engineered hemostatic biomaterials for sealing wounds | |
JP6408469B2 (ja) | ヒアルロン酸をベースとする薬物送達システム | |
CN105848649B (zh) | 用于免疫疗法的模块化粒子 | |
CA2840290C (en) | Procoagulant peptides and their derivatives and uses therefor | |
Dong et al. | Injectable adhesive hydrogel through a microcapsule cross-link for periodontitis treatment | |
Sahu et al. | Utility of nanomaterials in wound management | |
JP2014533988A5 (ja) | ||
Chan et al. | Synthetic strategies for engineering intravenous hemostats | |
JP2012025955A5 (ja) | ||
JP2002512947A5 (ja) | ||
JP2014530066A5 (ja) | ||
JP2017531659A5 (ja) | ||
TW201737925A (zh) | 對於防止黏連或止血有用之醫藥組成物 | |
ES2657901T3 (es) | Utilidad ampliada de las micropartículas derivadas de glóbulos rojos (RMP) para el tratamiento de la hemorragia | |
JP2018535952A5 (ja) | ||
RU2017115831A (ru) | Фармацевтические составы пегилированных липосом и факторов свертывания крови | |
CN106573057B (zh) | 含有血栓症治疗药的体液免疫诱导促进组合物及疫苗药物组合物 | |
WO2019152766A1 (en) | Antimicrobial platelet-like particles | |
Abzaeva et al. | Modern topical hemostatic agents and unique representatives of their new generation | |
JPWO2012011429A1 (ja) | 組織接着用シート製剤 | |
Liu et al. | Something between the amazing functions and various morphologies of self-assembling peptides materials in the medical field | |
Benedini et al. | Nanodevices for facing new challenges of medical treatments: stimuli-responsive drug delivery systems | |
WO2009063116A1 (es) | Empleo de micropartículas para su uso como vacunas y la liberación de moléculas biológicamente activas | |
Rajkumar et al. | Chitosan-Based Biomaterial in Wound Healing: A Review |